Cord Tissue mesenchymal Stem cells in the treatment of Covid 19
Advanced Therapy Medicinal Products under investigation (n=24) (wording taken from the titles of the registered studies)
10 out of 24 products that have been employeed in clinical trials for the treatment of Covid 19 are from perinatal tissues, mostly from cord tissue.
· Aerosol inhalation of vMIP: viral macrophage inflammatory protein
· Ankylosaurus; M1 macrophages target
· Anti-2019-nCoV inactivated convalescent plasma
· Anti-SARS-CoV-2 inactivated convalescent plasma
· Biological preparation of human placenta
· Convalescent plasma treatment
· Cord blood mesenchymal stem cells
· Human menstrual blood-derived stem cells
· Immunoglobulin from cured patients
· Inactivated Mycobacterium vaccine
· Infusion of convalescent plasma
· Mesenchymal stem cells
· Mesenchymal stem cells exosomes atomization
· mRNA-1273
· NK cells
· Plasma treatment
· Recombinant cytokine gene-derived protein injection
· Regulating intestinal flora
· Therapeutic antibody from recovered novel coronavirus pneumonia patients
· Umbilical cord blood mononuclear cells
· Umbilical cord mesenchymal stem cells (hucMSCs)
· Umbilical cord Wharton’s Jelly derived mesenchymal stem cells
· Umbilical Cord(UC)-derived mesenchymal stem cells
· Washed microbiota transplantation
Carl Heneghan is the Editor in Chief BMJ EBM and Professor of EBM, Centre for Evidence-Based Medicine in the Nuffield Department of Primary Care Health Sciences, University of Oxford Oxford https://www.cebm.net/covid-19/registered-trials-and-analysis/